{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "e7369e59",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.api_core once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.api_core past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.resourcemanager_v3 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.resourcemanager_v3 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1.schema.predict.instance_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1.schema.predict.instance_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1.schema.predict.params_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1.schema.predict.params_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1.schema.predict.prediction_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1.schema.predict.prediction_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1.schema.trainingjob.definition_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1.schema.trainingjob.definition_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1beta1.schema.predict.instance_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1beta1.schema.predict.instance_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1beta1.schema.predict.params_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1beta1.schema.predict.params_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1beta1.schema.predict.prediction_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1beta1.schema.predict.prediction_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1beta1.schema.trainingjob.definition_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1beta1.schema.trainingjob.definition_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/vertexai/generative_models/_generative_models.py:433: UserWarning: This feature is deprecated as of June 24, 2025 and will be removed on June 24, 2026. For details, see https://cloud.google.com/vertex-ai/generative-ai/docs/deprecations/genai-vertexai-sdk.\n",
      "  warning_logs.show_deprecation_warning()\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import sys\n",
    "import torch\n",
    "\n",
    "# Add src directory to path\n",
    "sys.path.insert(0, os.path.abspath('../src'))\n",
    "\n",
    "from parser import process_pdf\n",
    "from rag import build_rag_index_from_text\n",
    "from multiagent import DocumentMultiAgent\n",
    "from section_splitter import split_into_sections\n",
    "from section_classifier import embed, TARGET_QUERIES\n",
    "from structure_chunker import *\n",
    "from structured_retriever import *\n",
    "from agents import *"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "0a3d74ce",
   "metadata": {},
   "outputs": [],
   "source": [
    "parsed_data = process_pdf('../data/protocol.pdf')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8dfcfd3b",
   "metadata": {},
   "outputs": [],
   "source": [
    "parsed_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "a0dc8674",
   "metadata": {},
   "outputs": [],
   "source": [
    "chunks=build_structured_chunks(parsed_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "ed74968f",
   "metadata": {},
   "outputs": [],
   "source": [
    "retriever = BM25StructuredRetriever(chunks, TARGET_QUERIES)\n",
    "\n",
    "results = retriever.retrieve_context(\"eligibility\", top_k=3)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "76a3bedd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'================================================================\\nSection ID: 5.1\\nSection Path: STUDY  POPULATION > Inclusion Criteria\\nParticipants are eligible to be included inthe study only if all of the following criteria apply:\\nAge\\n================================================================\\n\\n5.1     Inclusion Criteria\\nParticipants are eligible to be included inthe study only if all of the following criteria apply:\\nAge\\n1  Adult, ≥ 18 years of age at thetime of consent\\nType of Participant\\n2  Increased risk of SARS-CoV-2 infection\\n  \\uf02d  Defined as adults whose locations or circumstances put them at appreciable risk of\\n     exposure to SARS-CoV-2 and COVID-19, based on available risk assessment\\n     contemporaneous to enrollment (believed to be at risk/exposure)\\n3  Medically stable such that, according to the judgment of the investigator, hospitalization\\n   within the study period is not anticipated and the participant appears likely to be able to\\n   remain on study through the end of protocol-specified follow-up\\n  \\uf02d  A stable medical condition is defined as disease not requiring significant change in\\n     therapy or hospitalization for worsening disease during the 3 months prior to\\n     enrollment\\n4  Able to understand and comply with study requirements/procedures (if applicable, with\\n   assistance by caregiver, surrogate, or legally authorized representative) based on the\\n   assessment of the investigator\\nReproduction\\n5  Contraceptive use by women should be consistent with local regulations regarding the\\n   methods of contraception for those participating in clinical studies\\n6  Female participants\\n   (a) Women of childbearing potential must:\\n      \\uf0b7  Have a negative pregnancy test on the day of screening and on Day 1\\n      \\uf0b7  Use one highly effective form of birth control for at least 28 days prior to Day 1\\n         and agree to continue using one highly effective form of birth control through\\n         60 days following administration of the second dose of study intervention.\\n         A highly effective method of contraception is defined as one that can achieve a\\n         failure rate of less than 1% per year when used consistently and correctly (see\\n         Table 6). Periodic abstinence, the rhythm method, and withdrawal are NOT\\n         acceptable methods of contraception.\\n\\n\\n   (b) Women are considered of childbearing potential unless they meet either of the\\n      following criteria:\\n      \\uf0b7  Surgically sterilized (including bilateral tubal ligation, bilateral oophorectomy, or\\n         hysterectomy), or\\n      \\uf0b7  Post-menopausal\\n         \\uf0b7  For women aged < 50 years, post-menopausal is defined as having both:\\n            o  A history of ≥ 12 months amenorrhea prior to randomization, without\\n               an alternative cause, following cessation of exogenous sex-hormonal\\n               treatment, and\\n            o  A follicle-stimulating hormone level in the post-menopausal range\\n            Until follicle-stimulating hormone is documented to be within menopausal\\n            range, the participant is to be considered of childbearing potential\\n         \\uf0b7  For women aged ≥ 50 years, post-menopausal is defined as having a history\\n            of ≥ 12 months amenorrhea prior to randomization, without an alternative\\n            cause, following cessation of exogenous sex-hormonal treatment\\n Table 6    Highly Effective Methods of Contraception\\n         | Barrier Methods                         | Hormonal Methods                                |\\n|:----------------------------------------|:------------------------------------------------|\\n| • Intrauterine device                   | • Combined (estrogen-and progestogen-containing |\\n| • Intrauterine hormone-releasing system | hormonal contraception)                         |\\n| (IUS) a                                 | Oral (combined pill)                            |\\n| • Bilateral tubal occlusion             | Intravaginal                                    |\\n| • Vasectomized partner b                | Transdermal (patch)                             |\\n| • Sexual abstinence c                   | • Progestogen-onlyhormonal contraception        |\\n|                                         | Oral                                            |\\n|                                         | Injectable                                      |\\n|                                         | Implantable                                     |\\n a  This is also considered a hormonal method\\n b  Provided that partner is the sole sexual partner of the woman of childbearing potentialstudy participant\\n    and that the vasectomized partner has received medical assessment of the surgical success\\n c  Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual\\n    intercourse from 28 days prior to Day 1 through 60 days following administration of the second dose of\\n    study intervention, and if it is the preferred and usual lifestyle of the participant\\nInformed Consent\\n7  Capable of giving signed informed consent as described in Appendix A, which includes\\n   compliance with the requirements and restrictions listed in the ICF and in this protocol\\n\\n================================================================\\nSection ID: 5.2\\nSection Path: STUDY  POPULATION > Exclusion Criteria\\nParticipants are excluded from the study if any of the following criteria apply:\\nMedical Conditions\\n1  History of allergy to any component of the vaccine\\n================================================================\\n\\n5.2     Exclusion Criteria\\nParticipants are excluded from the study if any of the following criteria apply:\\nMedical Conditions\\n1  History of allergy to any component of the vaccine\\n2  History of Guillain-Barré syndrome or any other demyelinating condition\\n3  Significant infection or other acute illness, including fever > 100 °F(> 37.8 °C) on the\\n   day prior to or day of randomization\\n4  History of laboratory-confirmed SARS-CoV-2 infection\\n5  Any confirmed or suspected immunosuppressive or immunodeficient state, including\\n   asplenia\\n6  Recurrent severe infections and use of immunosuppressant medication within the past\\n   6 months (≥ 20 mg per day of prednisone or its equivalent, given daily or on alternate\\n   days for ≥ 15 days within 30 days prior to administration of study intervention)\\n   The following exceptions are permitted:\\n   \\uf02d  Topical/inhaled steroids or short-term oral steroids (course lasting ≤ 14 days)\\n   \\uf02d  Human immunodeficiency virus-positive stable participants on stable antiretroviral\\n      therapy, eg, (NIH 2020, Waldrop et al 2016)\\n7  History of primary malignancy except for:\\n   (a) Malignancy with low potential risk for recurrence after curative treatment (for\\n      example, history of childhood leukaemia) or metastasis (for example, indolent\\n      prostate cancer) in the opinion of the site investigator.\\n   (b) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of\\n      disease\\n   (c) Adequately treated uterine cervical carcinoma in situ without evidence of disease\\n   (d) Localized prostate cancer\\n8  Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet\\n   disorder), or prior history of significant bleeding or bruising following IM injections or\\n   venepuncture\\n9  Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal\\n   disease, liver disease, renal disease, endocrine disorder, and neurological illness, as\\n   judged by the Investigator (mild/moderate well-controlled comorbidities are allowed)\\n10 Any other significant disease, disorder, or finding that may significantly increase the risk\\n   to the participant because of participation in the study, affect the ability of the participant\\n   to participate in the study, or impair interpretation of the study data\\n   Note: The AESIs as outlined in AppendixE (including Table 14) should be considered\\n   when evaluating a participant for ExclusionCriterion 10, as the presence of these AESIs,\\n\\n\\n   especially if untreated or uncontrolled, may be a safety risk to the participant, affect the\\n   ability of the participant to participate in the study, or impair interpretation of the study\\n   data. Investigators should review and consider the list of conditions in Appendix F. If any\\n   of these conditions are present in a participant, the Investigator is asked to utilize his/her\\n   clinical judgment in determining the participant’s eligibility for the study. Should the\\n   participant have conditions as outlined in AppendixE and the participant is enrolled, the\\n   Investigator is asked to document notes on site regarding the final rationale for\\n   enrollment.\\nPrior/Concomitant Therapy\\n11 Receipt of, or planned receipt of investigational products indicated for the treatment or\\n   prevention of SARS-CoV-2 or COVID-19\\n   Note: For participants who become hospitalized with COVID-19, receipt of licensed\\n   treatment options and/or participation in investigational treatment studies is permitted\\n12 Receipt of any vaccine (licensed or investigational) otherthan licensed influenza vaccines\\n   within 30 days prior to and after administration of study intervention\\n13 Receipt of immunoglobulins and/or any blood products within 3 months prior to\\n   administration of study intervention or expected receipt during the period of study\\n   follow-up\\nOther Exclusions\\n14 Involvement in the planning and/or conduct of this study (applies to both Sponsor staff\\n   and/or staff at the study site)\\n15 For women only - currently pregnant (confirmed with positive pregnancy test) or\\n   breast-feeding\\n16 Has donated ≥ 450 mL of blood products within 30 days prior to randomization or\\n   expects to donate blood within 90 days of administration of second dose of study\\n   intervention\\n\\n================================================================\\nSection ID: 5.3\\nSection Path: STUDY  POPULATION > Lifestyle Considerations\\n================================================================\\n\\n5.3     Lifestyle Considerations\\n1  Participants must follow the contraception requirements outlined in Section 5.1\\n2  Restrictions relating to concomitant medications are described in Section 6.5\\n3  Agree to wear digital health device if diagnosed with COVID-19 as described in\\n   Section8.1.2.2'"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "24bbd96b",
   "metadata": {},
   "outputs": [],
   "source": [
    "sections = split_into_sections(parsed_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "536e3714",
   "metadata": {},
   "outputs": [],
   "source": [
    "sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "a41f1781",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Agent configuration mapping\n",
    "AGENT_CONFIG = {\n",
    "    \"objectives\": {\n",
    "        \"target\": \"objectives and endpoints\",\n",
    "        \"function\": extract_objectives,\n",
    "    },\n",
    "    \"eligibility\": {\n",
    "        \"target\": \"eligibility\",\n",
    "        \"function\": extract_eligibility,\n",
    "    },\n",
    "    \"soa\": {\n",
    "        \"target\": \"schedule of activities\",\n",
    "        \"function\": extract_soa,\n",
    "    },\n",
    "    \"visit_definitions\": {\n",
    "        \"target\": \"visit_definitions\",\n",
    "        \"function\": extract_visit_definitions,\n",
    "    },\n",
    "    \"key_assessments\": {\n",
    "        \"target\": \"key_assessments\",\n",
    "        \"function\": extract_key_assessments,\n",
    "    },\n",
    "}\n",
    "\n",
    "\n",
    "# def _top_sections_for_target(sections, target, num_sections=2):\n",
    "#     section_titles = list(sections.keys())\n",
    "#     section_embeddings = embed(list(sections.keys()))\n",
    "\n",
    "#     query_embedding = embed([TARGET_QUERIES[target]])[0]\n",
    "#     scores = torch.matmul(section_embeddings, query_embedding)\n",
    "\n",
    "#     top_scores, top_indices = torch.topk(scores, k=min(num_sections, len(section_titles)))\n",
    "\n",
    "#     results = []\n",
    "#     for score, idx in zip(top_scores.tolist(), top_indices.tolist()):\n",
    "#         results.append((section_titles[idx], score))\n",
    "\n",
    "#     return results\n",
    "\n",
    "\n",
    "def run_agent_extraction(chunks, agent_name, num_sections=3):\n",
    "    \"\"\"\n",
    "    Run extraction for a specific agent.\n",
    "    \n",
    "    Args:\n",
    "        chunks: List of chunk objects with attributes like section_id, full_title, content\n",
    "        agent_name: One of \"objectives\", \"eligibility\", \"soa\", \"visit_definitions\", \"key_assessments\"\n",
    "        num_sections: Number of top sections to retrieve\n",
    "    \n",
    "    Returns:\n",
    "        Validated Pydantic model output from the agent\n",
    "    \"\"\"\n",
    "    if agent_name not in AGENT_CONFIG:\n",
    "        raise ValueError(f\"Unknown agent: {agent_name}. Must be one of {list(AGENT_CONFIG.keys())}\")\n",
    "    \n",
    "    config = AGENT_CONFIG[agent_name]\n",
    "    target = config[\"target\"]\n",
    "    extraction_func = config[\"function\"]\n",
    "    \n",
    "    # Get top relevant sections\n",
    "    retriever = BM25StructuredRetriever(chunks, TARGET_QUERIES)\n",
    "    top_sections = retriever.retrieve_context(target, top_k=num_sections)\n",
    "    \n",
    "    # Run extraction\n",
    "    return extraction_func(top_sections)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3188f1f8",
   "metadata": {},
   "outputs": [],
   "source": [
    "# objectives_output = run_agent_extraction(chunks, \"objectives\", num_sections=2)\n",
    "# eligibility_output = run_agent_extraction(sections, \"eligibility\", num_sections=2)\n",
    "# soa_output = run_agent_extraction(chunks, \"soa\", num_sections=2)\n",
    "# visit_definitions_output = run_agent_extraction(sections, \"visit_definitions\", num_sections=2)\n",
    "key_assessments_output = run_agent_extraction(chunks, \"key_assessments\", num_sections=5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7ad5d993",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "ObjectivesByCategory(primary=[Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19', endpoints=['A binary response, whereby a participant with negative serostatus at baseline is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs ≥15days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case.']), Objective(objective='To assess the safety and tolerability of 2IM doses of AZD1222 compared to saline placebo', endpoints=['Incidence of AEs for 28days post each dose of study intervention', 'Incidence of SAEs, MAAEs, and AESIs from Day 1 post treatment through Day 730']), Objective(objective='To assess the reactogenicity of 2 IM doses of AZD1222 compared to saline placebo', endpoints=['Incidence of local and systemic solicited AEs for 7days post each dose of study intervention'])], secondary=[Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of SARS-CoV-2 infection', endpoints=['The incidence of the first post-treatment response (negative at baseline to positive post treatment with study intervention) for SARS-CoV-2 Nucleocapsid antibodiesoccurring ≥15days post second dose of study interventionc']), Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of symptomatic COVID-19 using CDC criteria', endpoints=['The incidence of the first case of SARS-CoV-2 RT-PCR- positive symptomatic illness occurring ≥15days post second dose of study intervention using CDC criteria']), Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of University of Oxford-defined symptomatic COVID-19', endpoints=['The incidence of the first case of SARS-CoV-2 RT-PCR- positive symptomatic illness occurring ≥15days post second dose of study intervention using University of Oxford- defined symptom criteria']), Objective(objective='To estimate the efficacy of 2 IM dosesof AZD1222 compared to saline placebo in the prevention of COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection', endpoints=['The incidence of the first case of SARS-CoV-2 RT-PCR- positive symptomatic illness occurring ≥15days post second dose of study interventionregardless of evidence of prior SARS-CoV-2 infection c']), Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of severe or critical symptomaticCOVID-19', endpoints=['The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring ≥15days post second dose of study intervention c', 'The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring post first dose of study intervention']), Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19-related Emergency Department visits', endpoints=['The incidence of COVID-19-related Emergency Department visitsoccurring ≥15days post second dose of study interventionc']), Objective(objective='To assess antibody responses to AZD1222 Santigen following 2 IM doses of AZD1222 or saline placebo', endpoints=['Post-treatment GMTs and GMFRs from day of dosing baseline value to 28 days post each dose in SARS-CoV-2 S, RBDantibodies (MSD serology assay)', 'The proportion of participants who have a post-treatment seroresponse (≥4-fold rise in titers from day of dosing baseline value to 28 days post each dose) to the S, RBD antigens of AZD1222 (MSD serology assay)']), Objective(objective='To determine anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or saline placebo', endpoints=['Post-treatment GMTs and GMFRs from day of dosing baseline value to 28 days post each dose in SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay)', 'Proportion of participants who have a post-treatment seroresponse (≥4-fold rise in titers from day of dosing baseline value to 28 days post each dose) to AZD1222 as measured by SARS-CoV-2neutralizing antibodies (wild-typeassay or pseudo-neutralization assay)']), Objective(objective='To estimate the efficacy of AZD1222 compared to saline placebo for the prevention of COVID-19 following the first dose', endpoints=['The incidence of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring post first dose of study intervention'])], exploratory=[Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the all-cause mortality', endpoints=['The incidence of all-cause mortality from Day 1 through Day730']), Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for COVID-19-related deaths', endpoints=['The incidence of COVID-19-related deaths occurring from Day 1 through Day 730']), Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19-related hospitalizations', endpoints=['The incidence of COVID-19-related hospitalizations occurring ≥15days post second dose of study intervention', 'The incidence of COVID-19-related hospitalizations occurring post first dose of study intervention']), Objective(objective='To estimate the efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19-related ICU admissions', endpoints=['The incidence of COVID-19-related ICU admissions occurring ≥15days post second dose of study intervention', 'The incidence of COVID-19-related ICU admissions occurring post first dose of study intervention']), Objective(objective='To quantify SARS-Cov-2 viral loads in infected participants treated with 2 IM doses of AZD1222 or saline placebo', endpoints=['Viral genome copies in NP swabs collected at Illness Visits as determined by qRT-PCR']), Objective(objective='To characterize sequence variationsin SARS-CoV-2 through genotypic analyses in participants treated with 2 IM doses of AZD1222 or saline placebo', endpoints=['Genotypic analysis of SARS-CoV-2 from NP swabs collected on Day 1 illness visit']), Objective(objective='To quantify duration of viral shedding in symptomatic SARS-CoV-2 infected participants treated with 2 IM doses of AZD1222 or saline placebo', endpoints=['Duration of SARS-CoV-2 shedding in saliva over time']), Objective(objective='To assess the biometric profiles associated with COVID-19 using a biosensor in participants treated with 2IM doses of AZD1222 or saline placebo', endpoints=['Biophysical parameters, including but not limited to serial measurements of skin temperature, heart rate, respiratory rate, blood oxygen saturation, and physical activity, recorded using a biosensor from illness visits Day1 through Day28']), Objective(objective='To assess symptoms associated with COVID-19 using an e-Diary in participants treated with 2 IM doses of AZD1222 or saline placebo', endpoints=['Symptoms recorded by participants in an Illness e-Diary from illness visits Day 2 through Day 28']), Objective(objective='To assess SARS-CoV-2 specific antibodies in an ACE2 competition assay following 2 IM doses of AZD1222 or saline placebo', endpoints=['Post-treatment GMTs and GMFRs from Day 1 baseline value to 28 days post each dose in ACE2 competing antibodies from serum samples', 'Proportion of participants who have a post-treatment seroresponse (≥4-fold rise in titers from day of dosing baseline value to 28 days post each dose) in ACE2 competing antibodies']), Objective(objective='To assess B-and T-cell responses following 2 IM doses of AZD1222 or saline placebo', endpoints=['Quantification of (IFN-γ) ELISpot responses to SARS-CoV-2 S protein from day of dosing baseline to 14days post each dose', 'Intracellular cytokine staining and flow cytometry for B-and T-cell responses from day of dosing baseline to 14days post each dose']), Objective(objective='To assess SARS-CoV-2 antibodies in nasal secretions following 2 IM doses of AZD1222 or saline placebo', endpoints=['Post-treatment GMTs and GMFRs from Day 1 baseline value to 28 days post each dosein SARS-CoV-2 S, RBD, and Nucleocapsid antibodies (MSD serology assay)', 'Proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers from Day 1 baseline value to 28 days post each dose) to SARS-CoV-2 S, RBD, and Nucleocapsid antigens (MSD serology assay)']), Objective(objective='To assess anti-vector responses to the ChAdOx-1 adenovirus vector following 2 IM doses of AZD1222 or saline placebo', endpoints=['Proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers from Day 1 baseline value to 28 days post each dose) to AZD1222 as measured by ChAdOx1neutralizing antibodies']), Objective(objective='To assess additional immune responses following 2 IM doses of AZD1222 or saline placebo', endpoints=['Other exploratory assays for humoral and cellular immune responses may be performed basedupon emerging safety, efficacy, and immunogenicity data'])], other=[])"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# json printing for better readability\n",
    "print(json.dumps(key_assessments_output, indent=4))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "edb3ea82",
   "metadata": {},
   "outputs": [],
   "source": [
    "rag = build_rag_index_from_text(\n",
    "    text=parsed_data,\n",
    "    persist_dir=\"../data/rag_index\",\n",
    "    use_existing=False  # rebuild\n",
    ")\n",
    "\n",
    "question = \"What are the key assessments and procedures in this study?\"\n",
    "rag_answer = rag.answer(question, top_k=8)\n",
    "print(rag_answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "733c15f9",
   "metadata": {},
   "outputs": [],
   "source": [
    "multiagent = DocumentMultiAgent(sections, parsed_data)\n",
    "\n",
    "question = \"What are the key assessments and procedures in this study?\"\n",
    "response_json = multiagent.answer(question)\n",
    "print(response_json)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "219c642d",
   "metadata": {},
   "outputs": [],
   "source": [
    "response_json"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
